An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).
Inclusion Criteria:
Exclusion Criteria:
Nyíregyháza, Szabolcs-Szatmár-Bereg 4400, Hungary
Namdong-gu, Incheon 21565, South Korea
Iksan-si, Jeonlabuk-do, 54538, South Korea
Cantabria, Santa Cruz de Bezana 39109, Spain